A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Ocellaris Pharma, Inc.
Blueprint Medicines Corporation
Actym Therapeutics, Inc.
3B Pharmaceuticals GmbH
Telix Pharmaceuticals (Innovations) Pty Limited
Hutchmed
Mayo Clinic
Shanghai PerHum Therapeutics Co., Ltd.
Stanford University
Ipsen
pharmaand GmbH
Stanford University
Seagen Inc.
CureOne
MedInnovation GmbH
Kliniken Ludwigsburg-Bietigheim gGmbH
Stanford University
National Cancer Institute (NCI)